Should I buy or sell Actinium Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATNM shares. View ATNM analyst ratings or view top-rated stocks .

What is Actinium Pharmaceuticals' stock price target for 2024?

5 Wall Street analysts have issued 1 year price objectives for Actinium Pharmaceuticals' shares. Their ATNM share price targets range from $11.60 to $50.00. On average, they expect the company's share price to reach $25.72 in the next year. This suggests a possible upside of 274.4% from the stock's current price. View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts .

How have ATNM shares performed in 2024?

Actinium Pharmaceuticals' stock was trading at $5.24 at the start of the year. Since then, ATNM shares have increased by 31.1% and is now trading at $6.87. View the best growth stocks for 2024 here .

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,190,000 shares, an increase of 20.3% from the March 15th total of 1,820,000 shares. Based on an average daily volume of 332,600 shares, the days-to-cover ratio is currently 6.6 days. View Actinium Pharmaceuticals' Short Interest .

When is Actinium Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our ATNM earnings forecast .

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) released its quarterly earnings data on Monday, April, 3rd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.01.

When did Actinium Pharmaceuticals' stock split?

Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP) , Fitbit (FIT) , Global Ship Lease (GSL) , Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Gran Tierra Energy (GTE) , Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO) .

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.03%). View institutional ownership trends .

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:ATNM

Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis

→ Special FREE offer on stock hotsheets (From DTI) (Ad)

Free ATNM Stock Alerts

$6.67

-0.58 (-8.00%)

(As of 04:34 PM ET)

Compare

Today's Range: $6.66
▼
$7.51
50-Day Range: N/A
52-Week Range: $4.00
▼
$9.86

Volume: 419,567 shs
Average Volume: 330,182 shs
Market Capitalization: $196.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.72

Stock Analysis Analyst Forecasts Chart Earnings Headlines Ownership Short Interest

Get Actinium Pharmaceuticals alerts:

Actinium Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 274.4% Upside
$25.72 Price Target
Short Interest: Bearish
7.45% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.29
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.87) to $0.97 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.02 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Actinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Actinium Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.45% of the outstanding shares of Actinium Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Actinium Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in Actinium Pharmaceuticals has recently increased by 20.33%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Actinium Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Actinium Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATNM.

2.4

News and Social Media Coverage

News Sentiment
Actinium Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Actinium Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
53 people have searched for ATNM on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Actinium Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 27.50% of the stock of Actinium Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.87) to $0.97 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Actinium Pharmaceuticals is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Actinium Pharmaceuticals is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Actinium Pharmaceuticals has a P/B Ratio of 5.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About Actinium Pharmaceuticals Stock (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

ATNM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATNM Stock News Headlines

April 18, 2024 | markets.businessinsider.com

Actinium Says Phase 3 SIERRA Trial Results Of Iomab-B Shows Improving OS For AML Patients

April 18, 2024 | prnewswire.com

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 15, 2024 | investorplace.com

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

April 12, 2024 | msn.com

Meta Welcomes Developers to Threads with Open API Documentation

April 10, 2024 | venturebeat.com

OpenAI makes GPT-4 Turbo with Vision generally available through its API

April 9, 2024 | tmcnet.com

MyCompanyWorks launches EntityMachine™, the Innovative Business Entity Formation and Management API

April 9, 2024 | 9to5mac.com

Meta shares more details on Threads API ahead of June release

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 9, 2024 | finance.yahoo.com

The API Innovation Center, Apertus Pharmaceuticals Bring API Production of Critical Generic Cancer Drug to U.S. Soil

April 9, 2024 | finance.yahoo.com

Global Pharmaceutical CDMO Market Analysis Report 2024-2030: AI-Assisted Drug Active Pharmaceutical Ingredient (API) Synthesis Gaining Attention

April 9, 2024 | tmcnet.com

MEF Pioneers Industry Leading Enterprise Business and Operational LSO API Portfolio for Network Services

April 4, 2024 | stockhouse.com

Nextdoor Launches Ads API Program, Offering Advertisers an Easier Way to Extend Their Campaigns to Nextdoor

April 3, 2024 | markets.businessinsider.com

Actinium Pharmaceuticals: Strong Buy Rating on Financial Health and Promising Pipeline

April 2, 2024 | tmcnet.com

Hasura Supergraph Brings Unparalleled On-Demand Composability to APIs to Address Data and API Integration Challenges

April 2, 2024 | finance.yahoo.com

Global High Potency API Contract Manufacturing Market Expects Growth with a CAGR of 8.42% Through 2028

April 2, 2024 | finance.yahoo.com

Bitwarden Enhances Passwordless.dev Tools with Magic Links API to Streamline Passwordless Authentication

April 1, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)

April 1, 2024 | markets.businessinsider.com

Actinium's Phase 3 Trial Results Show Survival Benefit In Acute Myeloid Leukemia Patients; Stock Up

April 1, 2024 | finance.yahoo.com

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting

March 26, 2024 | finance.yahoo.com

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

March 26, 2024 | prnewswire.com

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

March 20, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Actinium Pharmaceuticals (ATNM)

March 19, 2024 | msn.com

Actinium spikes as H.C. Wainwright highlights buyout prospects after Fusion deal

March 16, 2024 | venturebeat.com

Forge’s API raises bar for player rewards and engagement

March 15, 2024 | finanznachrichten.de

Euroapi: Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy

March 15, 2024 | investorplace.com

High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment

See More Headlines

Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/03/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:ATNM
Previous Symbol: AMEX:ATNM
CUSIP: N/A
CIK: N/A
Web: www.actiniumpharmaceuticals.com
Phone: (646) 677-3870
Fax: N/A
Employees: 49
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $25.72
High Stock Price Target: $50.00
Low Stock Price Target: $11.60
Potential Upside/Downside: +254.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-48,820,000.00
Net Margins: N/A
Pretax Margin: -60,269.13%
Return on Equity: -102.64%
Return on Assets: -52.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.21
Quick Ratio: 9.21

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 2,664.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.31 per share
Price / Book: 5.53

Miscellaneous

Outstanding Shares: 29,400,000
Free Float: 28,220,000
Market Cap: $213.15 million
Optionable: Not Optionable
Beta: 0.01

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Sandesh C. Seth M.B.A. (Age 60)
M.S., Chairman & CEO
Comp: $1.15M
Mr. Steven O'Loughlin BS (Age 38)
CFO & Corporate Secretary
Comp: $585k
Dr. Paul Diamond Esq.
Ph.D., Vice President of Patent & Legal Counsel
Dr. David Gould
Senior Vice President of Corporate Development & Corporate Affairs
Dr. Bernie Cunningham P.M.P.
Ph.D., Executive Director of Clinical Supply Chain & Logistics and CMC Project Management
Dr. Qing Liang
VP & Head of Radiation Sciences
Dr. Avinash Desai M.D.
Chief Medical Officer
Ms. Jenny Hsieh
Chief Strategy Officer
Ms. Sunitha Lakshminarayanan
Senior VP, Head of CMC & Product Development
Ms. Elaina Haeuber
VP & Head of Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ATNM Stock Analysis - Frequently Asked Questions

Should I buy or sell Actinium Pharmaceuticals stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATNM shares.
View ATNM analyst ratings or view top-rated stocks.
What is Actinium Pharmaceuticals' stock price target for 2024?: 5 Wall Street analysts have issued 1 year price objectives for Actinium Pharmaceuticals' shares. Their ATNM share price targets range from $11.60 to $50.00. On average, they expect the company's share price to reach $25.72 in the next year. This suggests a possible upside of 274.4% from the stock's current price.
View analysts price targets for ATNM or view top-rated stocks among Wall Street analysts.
How have ATNM shares performed in 2024?: Actinium Pharmaceuticals' stock was trading at $5.24 at the start of the year. Since then, ATNM shares have increased by 31.1% and is now trading at $6.87.
View the best growth stocks for 2024 here.
Are investors shorting Actinium Pharmaceuticals?: Actinium Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,190,000 shares, an increase of 20.3% from the March 15th total of 1,820,000 shares. Based on an average daily volume of 332,600 shares, the days-to-cover ratio is currently 6.6 days.
View Actinium Pharmaceuticals' Short Interest.
When is Actinium Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024.
View our ATNM earnings forecast.
How were Actinium Pharmaceuticals' earnings last quarter?: Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) released its quarterly earnings data on Monday, April, 3rd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.01.

When did Actinium Pharmaceuticals' stock split?: Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of Actinium Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).
Who are Actinium Pharmaceuticals' major shareholders?: Actinium Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.03%).
View institutional ownership trends.
How do I buy shares of Actinium Pharmaceuticals?: Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ATNM) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial